$EBS (Emergent BioSolutions, Inc.)

$EBS {{ '2016-01-11T15:43:52+0000' | timeago}} • Announcement

For 2015, $EBS anticipates adjusted EPS of $1.54-1.63, the midpoint of which represents a 38% increase over 2014. For full year 2015, $EBS expects cash and cash equivalents at year end of about $310MM. EBITDA is projected to be $130-$134MM, the midpoint of which represents 43% increase over 2014.

$EBS {{ '2017-07-28T14:11:37+0000' | timeago}} • Announcement

$EBS and Valneva plan to initiate the Phase 1 trial in late 2017 or early 2018 and will share all costs until the availability of Phase 1 data, which is expected within six months from trial initiation. $EBS will have option to continue development arrangement with Valneva for milestone payment of EUR5MM, upon availability of Phase 1 data.

$EBS {{ '2017-07-28T14:10:27+0000' | timeago}} • Announcement

$EBS will pay Valneva EUR1MM upfront and will get exclusive rights to use Valneva’s intellectual property and know-how related to Zika product development. The companies are expected to enter into a technology transfer agreement at a later time to enable transfer of Valneva's technology to $EBS' Bayview manufacturing facility in Baltimore, MD.

$EBS {{ '2017-07-28T13:58:39+0000' | timeago}} • Announcement

$EBS announced a licensing agreement with Valneva SE for global exclusive rights to Valneva's Zika vaccine technology, ZIKV. Emergent and Valneva will co-develop ZIKV-VLA1601, a highly purified inactivated vaccine candidate against Zika virus, from preclinical development through completion of a Phase 1 safety and immunogenicity clinical trial.

$EBS {{ '2017-07-14T12:28:37+0000' | timeago}} • Announcement

$EBS has entered into an agreement to acquire the ACAM2000 business of Sanofi in an all-cash transaction with a total value of $125MM. The transaction, which is subject to customary closing conditions including antitrust regulatory approval, is expected to close in 2017.

$EBS {{ '2017-05-31T13:56:24+0000' | timeago}} • Announcement

$EBS has signed a modification to its contract with the Biomedical Advanced Research and Development Authority to produce and store bulk drug substance for its botulism antitoxin (BAT). The value of the deal is $53MM, with a 5-year performance period. BAT is indicated for treatment of symptomatic botulism following exposure to botulinum neurotoxin.

$EBS {{ '2017-03-31T12:52:41+0000' | timeago}} • Announcement

$EBS signed a modification to its contract with the Biomedical Advanced Research and Development Authority (BARDA) to manufacture and store bulk drug substance for its botulism antitoxin, BAT (Botulism Antitoxin Heptavalent), valued at about $53MM with a 5-year period of performance.

$EBS {{ '2017-02-13T13:12:00+0000' | timeago}} • Announcement

$EBS received a task order from the Biomedical Advanced Research and Development Authority (BARDA) valued at up to $30.5MM to develop monoclonal antibody therapeutics for viral hemorrhagic fever. This task order will utilize $EBS' Center for Innovation in Advanced Development and Manufacturing (CIADM) facility located in Baltimore, Maryland.

$EBS {{ '2017-02-01T14:32:53+0000' | timeago}} • Announcement

$EBS initiated a Phase 1b multiple ascending dose study to evaluate safety and tolerability of UV-4B, its novel antiviral candidate being developed as potential oral treatment for dengue viral infection. This study, which will enroll 40 healthy adults in U.S. sites, follows successful Phase 1a single ascending dose clinical study completed in 2016.

$EBS {{ '2016-12-12T13:49:07+0000' | timeago}} • Announcement

$EBS reported that Health Canada has approved the company’s New Drug Submission for BAT, a drug for treating a potentially fatal disease. The company has an existing ten-year contract, executed in 2012, to supply BAT to the Canadian Department of National Defense, the Public Health Agency of Canada and individual provincial health authorities.

$EBS {{ '2016-12-09T12:40:11+0000' | timeago}} • Announcement

On continuing operations basis, $EBS now expects 2016 total revenue of $465-485MM, BioThrax sales of $220-235MM, net income of $50-60MM and adjusted net income of $65-75MM. On a combined basis, $EBS now expects 2016 total revenue of $485-505MM, net income of $35-45MM and adjusted net income of $55-65MM.

$EBS {{ '2016-12-09T12:37:52+0000' | timeago}} • Announcement

$EBS signed follow-on contract with CDC valued at up to $911MM to supply to the Strategic National Stockpile (SNS) about 29.4MM doses of BioThrax through September 2021. BARDA issues notice of intent to separately procure about $100MM of BioThrax for SNS over 24 months from contract award, which is expected in 1H17

$EBS {{ '2016-12-09T12:36:33+0000' | timeago}} • Announcement

$EBS said U.S. Department of Health and Human Services is advancing its anthrax preparedness strategy with multiple contract actions for $EBS' anthrax vaccines. $EBS signed follow-on contract with the Centers for Disease Control and Prevention.

$EBS {{ '2016-09-30T13:45:00+0000' | timeago}} • Announcement

$EBS signed a multi-year contract with the Biomedical Advanced Research and Development Authority, for the advanced development and delivery of NuThrax, $EBS' next generation anthrax vaccine candidate. The contract is valued at up to approx. $1.6Bil & consists of a 5-year base period of performance valued at approx. $200MM to develop NuThrax.

$EBS {{ '2016-07-15T18:30:02+0000' | timeago}} • Announcement

Specialty biopharmaceutical company $EBS said that its Board of Directors has authorized the management to implement a stock repurchase program for up to $50MM of common stock from time to time on the open market or in privately negotiated transactions. The term of the authorization of the repurchase program is until Dec. 31, 2017.

$EBS {{ '2016-07-11T17:52:02+0000' | timeago}} • Announcement

$EBS said that its BoD declared a dividend distribution of one share of Aptevo Therapeutics Inc. common stock for every two shares of its common stock outstanding as of the close of business on July 22, 2016, the record date for the distribution. $EBS expects to complete the distribution of Aptevo common stock to its stockholders on Aug. 1, 2016.

$EBS {{ '2016-07-11T17:51:49+0000' | timeago}} • Announcement

$EBS said that its BoD approved the spin-off of Aptevo Therapeutics Inc. There is currently no market for Aptevo common stock and Aptevo expects its common stock to begin trading on a "when issued" basis shortly before the July 22, 2016 record date under the ticker "APVO WI."

$EBS {{ '2016-06-15T18:16:49+0000' | timeago}} • Announcement

Biopharma company $EBS said the US FDA has granted Orphan Drug status for BioThrax for post-exposure prophylaxis of anthrax disease resulting from exposure to Bacillus anthracis. The Orphan Drug status provides market exclusivity through Nov. 2022, which is 7 years from the date on which FDA approved the PEP indication for BioThrax.

$EBS {{ '2016-04-20T15:48:18+0000' | timeago}} • Announcement

$EBS said it presented preclinical data on its bispecific ADAPTIR (modular protein technology) molecule, ES425, at the American Association for Cancer Research Annual Meeting in New Orleans, Louisiana. The ES425 molecule is being developed as a potential therapeutic for triple-negative breast cancer (TNBC).

$EBS {{ '2016-04-15T22:16:09+0000' | timeago}} • Announcement

$EBS said that it had done the initial filing of Form 10 with SEC with respect to the previously planned spin-off of certain assets of its biosciences business to create a separate, publicly-traded company, Aptevo Therapeutics Inc. The spin-off is expected to complete in mid-2016.

$EBS {{ '2016-02-17T12:44:25+0000' | timeago}} • Announcement

Specialty biopharma company $EBS said that its military-grade auto-injector platform, Emergard, has been selected by the US DoD and the Battelle Memorial Institute to be tested against and developed to US military specifications as a platform for nerve agent antidote delivery. Emergard development and testing is expected to be completed in 2016.

Recent Transcripts

IMUC (ImmunoCellular Therapeutics, Ltd.)
Wednesday, August 23 2017 - 9:00pm
ONVO (Organovo Holdings, Inc.)
Wednesday, August 9 2017 - 9:00pm
NKTR (Nektar Therapeutics)
Tuesday, August 8 2017 - 9:00pm
ACHN (Achillion Pharmaceuticals, Inc.)
Tuesday, August 8 2017 - 8:05pm
ZTS (Zoetis Inc.)
Tuesday, August 8 2017 - 12:30pm
VRX (Valeant Pharmaceuticals International, Inc.)
Tuesday, August 8 2017 - 12:00pm
EBS (Emergent BioSolutions, Inc.)
Thursday, August 3 2017 - 9:00pm
TXMD (TherapeuticsMD, Inc.)
Thursday, August 3 2017 - 8:30pm
REGN (Regeneron Pharmaceuticals, Inc.)
Thursday, August 3 2017 - 12:30pm
SYN (Synthetic Biologics Inc.)
Thursday, August 3 2017 - 12:30pm
AGN (Allergan plc)
Thursday, August 3 2017 - 12:30pm
TRXC (TransEnterix, Inc.)
Wednesday, August 2 2017 - 8:30pm
BMRN (BioMarin Pharmaceutical Inc.)
Wednesday, August 2 2017 - 8:30pm
CELG (Celgene Corporation)
Thursday, July 27 2017 - 1:00pm
ALKS (Alkermes plc)
Thursday, July 27 2017 - 12:30pm
VRTX (Vertex Pharmaceuticals Incorporated)
Wednesday, July 26 2017 - 9:15pm
GSK (GlaxoSmithKline plc)
Wednesday, July 26 2017 - 1:00pm
ONVO (Organovo Holdings, Inc.)
Wednesday, June 7 2017 - 9:00pm
PTN (Palatin Technologies Inc.)
Tuesday, May 16 2017 - 3:00pm
SCLN (SciClone Pharmaceuticals, Inc.)
Wednesday, May 10 2017 - 8:30pm

AlphaGraphics you may like